Arcellx, Inc. (ACLX)

114.77 +0.02 (+0.02%) USD  |  NASDAQ  |  Apr 02, 16:00
114.93 +0.16 (+0.14%) After-Hours: 05:06
More

Arcellx SG&A Expense (TTM) : 117.76M for Dec. 31, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ACLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Gilead Sciences, Inc. 8.398B
Eli Lilly & Co. 11.09B
Merck & Co., Inc. 10.73B
Bristol Myers Squibb Co. 7.267B
BioMarin Pharmaceutical, Inc. 1.153B